A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

[1]  T. Karachalios,et al.  Calcitonin effects on rabbit bone. Bending tests on ulnar osteotomies. , 1992, Acta orthopaedica Scandinavica.

[2]  M. Holtrop,et al.  THE EFFECTS OF PARATHYROID HORMONE, COLCHICINE, AND CALCITONIN ON THE ULTRASTRUCTURE AND THE ACTIVITY OF OSTEOCLASTS IN ORGAN CULTURE , 1974, The Journal of cell biology.

[3]  J. Reginster,et al.  1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN , 1987, The Lancet.

[4]  J. Reginster,et al.  The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis , 1998 .

[5]  B. Riis,et al.  Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. , 1990, The American journal of medicine.

[6]  M. Dambacher,et al.  Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. , 1988, The Journal of clinical endocrinology and metabolism.

[7]  L. Mosekilde,et al.  The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. , 1994, Endocrinology.

[8]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[9]  R. Baron,et al.  Behavior of osteoclasts during a rapid change in their number induced by high doses of parathyroid hormone or calcitonin in intact rats , 1981 .

[10]  Ying Lu,et al.  Dual X‐ray absorptiometry quality control: Comparison of visual examination and process‐control charts , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  G. Thamsborg.  Effect of nasal salmon calcitonin on calcium and bone metabolism. , 1999, Danish medical bulletin.

[12]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  R. Littell.  SAS System for Mixed Models , 1996 .

[14]  A. Grauer,et al.  In vitro detection of neutralizing antibodies after treatment of paget's disease of bone with nasal salmon calcitonin , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[16]  L. Melton,et al.  Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. , 1996, Bone.

[17]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[18]  P. Symeonides,et al.  A double blind study of intranasal calcitonin for established postmenopausal osteoporosis. , 1997, Acta orthopaedica Scandinavica. Supplementum.

[19]  D. Baylink,et al.  Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. , 1994, Clinical chemistry.

[20]  C. Christiansen,et al.  NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS , 1989, Clinical endocrinology.

[21]  H. Genant,et al.  Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.

[22]  H K Genant,et al.  Comparative calibration without a gold standard. , 1997, Statistics in medicine.

[23]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[24]  S. Krane,et al.  An evaluation of antibodies and clinical resistance to salmon calcitonin. , 1972, The Journal of clinical investigation.

[25]  S. Hilsenbeck,et al.  Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. , 1995, The Journal of clinical investigation.

[26]  M. Azria.  The Calcitonins: Physiology and Pharmacology , 1989 .

[27]  J. Reginster,et al.  A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. , 1995, The American journal of medicine.

[28]  P. Delmas,et al.  Measurement of serum osteocalcin with a human‐specific two‐site immunoradiometric assay , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  C. Minkin,et al.  Ultrastructural effects of calcitonin on osteoclasts in tissue culture. , 1972, Journal of ultrastructure research.

[30]  P. Franchimont,et al.  A 5‐year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium , 1994, European journal of clinical investigation.

[31]  G. Van der Perre,et al.  Effect of Salmon Calcitonin on Femoral Bone Quality in Adult Ovariectomized Ewes , 1996, Calcified Tissue International.

[32]  S. Cummings,et al.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .

[33]  C. Cooper,et al.  The crippling consequences of fractures and their impact on quality of life. , 1997, The American journal of medicine.

[34]  D. Dempster,et al.  Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[36]  J. Reginster,et al.  Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[38]  B. Riis,et al.  Effect of salcatonin given intranasally on early postmenopausal bone loss. , 1989, BMJ.

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .

[40]  O. Johnell,et al.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. , 1992, BMJ.